Skip to main content

Table 1 Descriptive characteristics of study participants

From: Association between physical activity and metabolic syndrome in middle-aged Japanese: a cross-sectional study

 

Men (n = 179)

Women (n = 304)

Pvalue

Age (years)

46.6 (0.6)

48.6 (0.5)

0.015

Height (cm)

170 (0.5)

157.7 (0.3)

< 0.001

Body weight (kg)

73.9 (0.9)

63.7 (0.6)

< 0.001

BMI (kg/m2)

25.6 (0.3)

25.6 (0.2)

0.896

% muscle mass (%)

30.4 (0.2)

23.7 (0.3)

< 0.001

% fat mass (%)

25.1 (0.4)

34.0 (0.4)

< 0.001

Physical activity parameter *

   

   Sedentary time (h/week)

37.2 (0.9)

29.5 (0.7)

< 0.001

   Low intensity activity (METs h/week)

77.1 (1.8)

96.4 (1.3)

< 0.001

   MVPA (METs h/week)

24.5 (0.8)

25.7 (0.6)

0.252

Metabolic syndrome components

   

   Abdominal obesity (%)

66.7

43.9

< 0.001

   Hyperglycemia (%)

29.8

18.8

0.005

   Hypertension (%)

54.2

47.7

0.168

   Dyslipidemia (%)

33.5

14.5

< 0.001

   Number of MetS components (n)

1.9 (0.1)

1.3 (0.1)

< 0.001

Metabolic syndrome

  

< 0.001

   Pre-MetS (%)

18.4

17.8

 

   MetS (%)

34.6

16.4

 

   MetS/pre-MetS (%)

53.1

34.2

 

Daily nutritional intake †

   

   Calorie intake (kcal/day)

2126.1 (24)

1899.1 (15.6)

< 0.001

   Carbohydrate intake (g/day)

253.0 (7)

238.6 (4.8)

0.081

   Protein intake (g/day)

76.9 (1.9)

68.6 (1.6)

0.010

   Fat intake (g/day)

60.0 (1.8)

55.5 (1.5)

0.058

Smoker (%)

22.3

5.3

< 0.001

Postmenopausal (%)

-

52.6

 
  1. Values are means (SE) or percentage. *Adjusted for age, †adjusted for body weight. BMI, body mass index; METs, metabolic equivalents; MVPA, moderate-vigorous physical activity; MetS, metabolic syndrome; SE, standard error. Abdominal obesity: waist circumference ≥ 85 cm for men and ≥ 90 cm for women; hyperglycemia: blood glucose ≥ 110 mg/dL; hypertension: systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 85 mmHg, or treatment for previously diagnosed hypertension; dyslipidemia: triglyceride ≥ 150 mg/dL and/or high-density lipoprotein cholesterol level < 40 mg/dL, or specific treatment for these lipid abnormalities.